Skip to main content
Premium Trial:

Request an Annual Quote

CGC Genetics Opens US HQ in New Jersey

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Portuguese genetic testing company CGC Genetics has opened its US headquarters in Newark, NJ, and has established an affiliation agreement with the Institute of Genomic Medicine (IGM) at Newark's New Jersey Medical School.

The company held a ribbon-cutting for the facility with Newark Mayor Corey Booker and other representatives from city government last week.

CGC Genetics offers more than 1,500 genetic tests for prenatal screening, diagnostics, and pharmacogenetics in a range of areas including oncology and other common and rare diseases.

CGC and IGM share complementary genetic diagnostics technologies, the company said late last week, including "a broad menu of clinical tests that cover almost every genetic test available and a significant R&D infrastructure ensuring the rapid development and availability of new tests to CGC clients and partners."

CGC was wooed to New Jersey in part by efforts from the City of Newark and by Brick City Development Corporation, both of which traveled to Portugal three times in recent years and hosted Portuguese companies through a business attraction campaign.

"Our medical genetic business will benefit from Newark's convenient location, extensive infrastructure, and prestigious medical schools," CGC Genetics' CEO Purificação Tavares said in a statement.

CGC Genetics has facilities and offices in Oporto and Lisbon in Portugal, in Madrid, and in New York City.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.